245 related articles for article (PubMed ID: 20018890)
1. SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway.
Su B; Bu Y; Engelberg D; Gelman IH
J Biol Chem; 2010 Feb; 285(7):4578-86. PubMed ID: 20018890
[TBL] [Abstract][Full Text] [Related]
2. Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling, and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12.
Guo LW; Gao L; Rothschild J; Su B; Gelman IH
J Biol Chem; 2011 Nov; 286(44):38356-38366. PubMed ID: 21903576
[TBL] [Abstract][Full Text] [Related]
3. Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12.
Su B; Gao L; Meng F; Guo LW; Rothschild J; Gelman IH
Oncogene; 2013 Apr; 32(16):2016-26. PubMed ID: 22710722
[TBL] [Abstract][Full Text] [Related]
4. SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways.
Gelman IH; Gao L
Mol Cancer Res; 2006 Mar; 4(3):151-8. PubMed ID: 16547152
[TBL] [Abstract][Full Text] [Related]
5. Suppression of chemotaxis by SSeCKS via scaffolding of phosphoinositol phosphates and the recruitment of the Cdc42 GEF, Frabin, to the leading edge.
Ko HK; Guo LW; Su B; Gao L; Gelman IH
PLoS One; 2014; 9(10):e111534. PubMed ID: 25356636
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.
Gelman IH
Cancer Metastasis Rev; 2012 Dec; 31(3-4):493-500. PubMed ID: 22684366
[TBL] [Abstract][Full Text] [Related]
7. Control of cytoskeletal architecture by the src-suppressed C kinase substrate, SSeCKS.
Gelman IH; Lee K; Tombler E; Gordon R; Lin X
Cell Motil Cytoskeleton; 1998; 41(1):1-17. PubMed ID: 9744295
[TBL] [Abstract][Full Text] [Related]
8. Role for transcription factor TFII-I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src.
Bu Y; Gao L; Gelman IH
Int J Cancer; 2011 Apr; 128(8):1836-42. PubMed ID: 20568114
[TBL] [Abstract][Full Text] [Related]
9. SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.
Lin X; Nelson P; Gelman IH
Mol Cell Biol; 2000 Oct; 20(19):7259-72. PubMed ID: 10982843
[TBL] [Abstract][Full Text] [Related]
10. Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12.
Akakura S; Nochajski P; Gao L; Sotomayor P; Matsui S; Gelman IH
Cell Cycle; 2010 Dec; 9(23):4656-65. PubMed ID: 21099353
[TBL] [Abstract][Full Text] [Related]
11. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis.
Lin X; Gelman IH
Cancer Res; 1997 Jun; 57(11):2304-12. PubMed ID: 9187136
[TBL] [Abstract][Full Text] [Related]
12. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition.
Su B; Zheng Q; Vaughan MM; Bu Y; Gelman IH
Cancer Res; 2006 Jun; 66(11):5599-607. PubMed ID: 16740695
[TBL] [Abstract][Full Text] [Related]
13. Receptor-mediated Ca2+ and PKC signaling triggers the loss of cortical PKA compartmentalization through the redistribution of gravin.
Schott MB; Grove B
Cell Signal; 2013 Nov; 25(11):2125-35. PubMed ID: 23838009
[TBL] [Abstract][Full Text] [Related]
14. SSeCKS/Gravin/AKAP12 Inhibits PKCĪ¶-Mediated Reduction of ERK5 Transactivation to Prevent Endotoxin-Induced Vascular dysfunction.
Li Z; Hu J; Guo J; Fan L; Wang S; Dou N; Zuo J; Yu S
Cardiovasc Toxicol; 2019 Aug; 19(4):372-381. PubMed ID: 30805771
[TBL] [Abstract][Full Text] [Related]
15. A role for SSeCKS, a major protein kinase C substrate with tumour suppressor activity, in cytoskeletal architecture, formation of migratory processes, and cell migration during embryogenesis.
Gelman IH; Tombler E; Vargas J
Histochem J; 2000 Jan; 32(1):13-26. PubMed ID: 10805381
[TBL] [Abstract][Full Text] [Related]
16. Activation of protein kinase C betaII/epsilon-c-Jun NH2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin.
Miyata Y; Sato T; Yano M; Ito A
Mol Cancer Ther; 2004 Jul; 3(7):839-47. PubMed ID: 15252145
[TBL] [Abstract][Full Text] [Related]
17. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer.
Xia W; Unger P; Miller L; Nelson J; Gelman IH
Cancer Res; 2001 Jul; 61(14):5644-51. PubMed ID: 11454719
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17F-induced pulmonary microvascular endothelial monolayer hyperpermeability via the protein kinase C pathway.
You QH; Sun GY; Wang N; Shen JL; Wang Y
J Surg Res; 2010 Jul; 162(1):110-21. PubMed ID: 19577259
[TBL] [Abstract][Full Text] [Related]
19. Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: correlation with culture confluency, cell cycle phase and serum response.
Nelson PJ; Gelman IH
Mol Cell Biochem; 1997 Oct; 175(1-2):233-41. PubMed ID: 9350056
[TBL] [Abstract][Full Text] [Related]
20. SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.
Liu Y; Gao L; Gelman IH
BMC Cancer; 2006 Apr; 6():105. PubMed ID: 16638134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
